Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Generic Drug Applications Will Cost Less In FY 2020

Executive Summary

Increases in the number of expected ANDA submissions, facilities and entities holding approved applications means lower user fees in most GDUFA II categories starting 1 October; program fee will see the largest percentage drop, amounting to savings of $200,000 for large companies.


You may also be interested in...

US FDA Generic Approvals Break 900 Barrier In FY 2019

The record number of full ANDA approvals also exceeded submissions for the first time since GDUFA was enacted.

FDA Obscura: GDUFA Fee Calculations Took CBER-Regulated ANDAs Into Account

ANDAs regulated by the US FDA's biologics center, some pre-1984 conditional approvals, and others were factored into GDUFA program fee calculations.

PDUFA Application Fee Nears $3m Threshold In FY 2020

The US FDA fee for a new drug or biologics license application requiring clinical data will jump to $2.94m in October.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts